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Recessive Dystrophic Epidermolysis Bullosa Mice
Yingping Hou1, Lin T. Guey2, Timothy Wu1, Robert Gao1, Jon Cogan1, Xinyi Wang1, Elizabeth Hong1,
Weihuang Vivian Ning1, Douglas Keene3, Nan Liu2, Yan Huang2, Craig Kaftan2, Bruce Tangarone2,
Igor Quinones-Garcia2, Jouni Uitto4, Omar L. Francone2, David T. Woodley1 and Mei Chen1
Recessive dystrophic epidermolysis bullosa (RDEB) is an inherited disorder characterized by skin fragility,
blistering, and multiple skin wounds with no currently approved or consistently effective treatment. It is due to
mutations in the gene encoding type VII collagen (C7). Using recombinant human C7 (rhC7) puriﬁed from
human dermal ﬁbroblasts (FB-rhC7), we showed previously that intravenously injected rhC7 distributed to
engrafted RDEB skin, incorporated into its dermal–epidermal junction (DEJ), and reversed the RDEB disease
phenotype. Human dermal ﬁbroblasts, however, are not used for commercial production of therapeutic
proteins. Therefore, we generated rhC7 from Chinese hamster ovary (CHO) cells. The CHO–derived
recombinant type VII collagen (CHO-rhC7), similar to FB-rhC7, was secreted as a correctly folded, disulﬁde-
bonded, helical trimer resistant to protease degradation. CHO-rhC7 bound to ﬁbronectin and promoted human
keratinocyte migration in vitro. A single dose of CHO-rhC7, administered intravenously into new-born C7-null
RDEB mice, incorporated into the DEJ of multiple skin sites, tongue and esophagus, restored anchoring ﬁbrils,
improved dermal–epidermal adherence, and increased the animals’ life span. Furthermore, no circulating or
tissue-bound anti-C7 antibodies were observed in the mice. These data demonstrate the efﬁcacy of CHO-rhC7 in
a preclinical murine model of RDEB.
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INTRODUCTION
Type VII collagen (C7) is the major component of anchoring
ﬁbrils (AFs), attachment structures in the dermal–epidermal
junction (DEJ) of the skin that serve to adhere the epidermal
layer of the skin onto the dermis (Sakai et al., 1986; Lin
and Carter, 1992; Burgeson, 1993). It is composed of three
identical α-chains, each consisting of a 145-kDa central
collagenous triple-helical segment, ﬂanked by a large
145-kDa amino-terminal, noncollagenous domain (NC1), and
a small 34-kDa carboxyl-terminal non-collagenous domain
(NC2) (Lunstrum et al., 1986; Burgeson et al., 1990). Within the
extracellular space, C7 molecules form antiparallel dimers that
aggregate laterally to form AFs. Our study using recombinant
NC1 demonstrated that NC1 interacts with various extracellular
matrix components including ﬁbronectin, laminin 332, type I
collagen, and type IV collagen (Chen et al., 1997b, 1999).
Further, we demonstrated that C7 is the primary extracellular
matrix protein that most potently promotes human keratinocyte
migration (Woodley et al., 2008).
Defects in the C7 gene, designated COL7A1, result in
hereditary dystrophic epidermolysis bullosa (DEB) (Uitto and
Christiano, 1992, 1994). DEB is a group of heritable mechano-
bullous skin diseases characterized by skin fragility, separation
of the epidermis from the dermis (blister formation), milia, and
scarring. The DEJ of patients with DEB is characterized by a
paucity or a diminutive size of AFs (Lin and Carter, 1992). RDEB
skin wounds heal with marked ﬁbrosis, contraction, and
scarring (Fine et al., 2008). RDEB is often lethal because of an
aggressive squamous cell carcinoma that develops within a
chronically open wound or scar area (Fine et al., 2009).
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The current mainstays of treatment for RDEB are palliative
interventions, which primarily consist of bandaging of the skin,
and nutritional sustenance (Fine et al., 2014). Unfortunately, to
date, there are no approved treatments for RDEB, thus
generating numerous investigations toward developing
successful treatments. Although there are no currently
approved treatments for RDEB, several investigative groups
are developing various therapies for RDEB including ex vivo
gene therapy, cell therapy, and protein replacement therapy
(Ortiz-Urda et al., 2002; Chen et al., 2002b; Woodley et al.,
2003, 2004a, 2004b; Wong et al., 2008; Remington et al.,
2009; Wagner et al., 2010).
C7 is an unusual collagen that, unlike other collagens, can
be soluble in neutral buffer and blood and does not initiate the
clotting cascade or platelet aggregation (Saelman et al., 1994).
We have recently been exploring the possibility of delivering
C7 intravenously. This would have the advantage of delivering
C7 simultaneously to multiple skin wounds and wounds in the
oral mucosa and esophagus. We showed that intravenously
injected, molecularly engineered RDEB ﬁbroblasts
(overexpressing human C7) and ﬁbroblast-derived recombi-
nant C7 (FB-rhC7) itself distributed to murine skin wounds,
incorporated into the skin’s DEJ, formed AF structures, and
accelerated wound closure (Woodley et al., 2007, 2013).
Although our genetically engineered human dermal ﬁbro-
blast cell line is an excellent source for producing large
quantities of puriﬁed rhC7, human dermal ﬁbroblasts are not
currently used for large-scale commercial production of
therapeutic proteins. Chinese hamster ovary (CHO) cells, in
contrast, are commonly used for large-scale production of
therapeutic proteins (Jayapal et al., 2007; Kim et al., 2012).
We have expressed recombinant human C7 in a CHO cell
line using a eukaryotic expression vector and generated
rhC7 molecules in sufﬁcient amounts for biological
characterization and further functional analysis. Our
structural and functional characterization of rhC7 puriﬁed
from CHO cells (CHO-rhC7) shows that CHO-derived rhC7 is
similar to FB-rhC7 based on a number of physicochemical
assessments. We also evaluated the efﬁcacy of intravenously
administration of CHO-rhC7 in the neonatal C7-null
(Col7a1− /−) mouse model. We showed that the intravenously
injected CHO-rhC7 distributed and incorporated into the DEJ
of RDEB mice at multiple skin sites as well as the tongue and
esophagus and formed AFs. As a consequence, intravenous
administration of CHO-rhC7 signiﬁcantly improved the RDEB
murine phenotype as demonstrated by reduced dermal–
epidermal separation and markedly prolonged survival.
Furthermore, we did not detect any tissue deposited or
circulating anti-human C7 antibodies in any of the neonatal
RDEB mice administered a single intravenous injection of
CHO-rhC7. These data provide evidence of intravenous
CHO-rhC7 injection in RDEB-like C7 knockout mice with
improvement of key features of the disease. Finally, these data
show that molecularly engineered CHO cells are capable of
synthesizing and secreting a large human extracellular matrix
macromolecule that retains the physical and functional
attributes of the authentic human protein.
RESULTS
Characterization of structural properties for CHO-rhC7
As shown in Figure 1a, CHO-rhC7 migrates at the same
position as FB-rhC7 (Figure 1a). In addition, similar to FB-
rhC7, CHO-rhC7 was also glycosylated (Figure 1b). When the
puriﬁed CHO-rhC7 was subjected to 4–12% SDS-PAGE
under non-reducing conditions (Figure 1c), it migrated at the
same position as FB-rhC7 with an apparent molecular weight
of 870 kDa, in agreement with the reported molecular weight
of an rhC7 trimer (Chen et al., 2002a).
To determine whether the rhC7 trimers formed in vitro are
stable and have a proper triple-helical conformation in their
collagenous domain, the puriﬁed rhC7 was treated with
chymotrypsin and then subjected to immunoblot analysis
using a polyclonal antibody against the triple-helical domain.
Under these digestion conditions, the noncollagenous NC1
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Figure 1. Structural characterization of recombinant human C7 puriﬁed from human dermal ﬁbroblasts (FB-rhC7) and Chinese hamster ovary–cells (CHO-
rhC7). A measure of 2 μg of puriﬁed rhC7 was subjected to 6% SDS-PAGE and (a) Coomassie Blue staining and (b) the Pierce Glycoprotein Staining Kit. (c) A
measure of 0.2 μg of puriﬁed rhC7 was subjected to 4–15% SDS-PAGE under non-reducing conditions, followed by immunoblot analysis with a polyclonal
antibody to N-terminal noncollagenous domain of type VII collagen (NC1). (d) Puriﬁed rhC7 was incubated with chymotrypsin and analyzed by 6% SDS-PAGE,
followed by immunoblot analysis with a polyclonal antibody to the triple-helical domain (TH). (e) Schematic shows that NC1 is held by disulﬁde bonds into a
trident-like shape. Within the TH is a “hinge region”, which is non-helical and protease sensitive. Protease digestion of the triple helix of C7 leads to partial
cleavage of the “hinge region” and creates two short triple helical fragments. Lane 1: CHO-rhC7; lane 2: FB-rhC7. The positions of molecular weight markers,
monomer (M) and homotrimer (T) of C7, the 200 kDa intact TH, and the 190 kDa carboxyl-terminal half (the P1 fragment), are indicated.
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and NC2 domains were removed. The triple-helical domain is
resistant to digestion, with the exception of cleavage into the
P1 and P2 fragments (Figure 1e), as previously described by
Burgeson (1993). As shown in Figure 1d, digestion of both the
290-kDa CHO-rhC7 and FB-rhC7 with chymotrypsin yielded
200 and 119 kDa fragments that were resistant to further
protease degradation, corresponding to the intact triple-
helical domain (TH) and its carboxyl-terminal half, the P1
fragment. These data suggest that similar to FB-rhC7, CHO-
rhC7 forms a triple helix with a collagenous domain resistant
to protease digestion.
CHO-rhC7 binds to ﬁbronectin and promotes cell migration
We previously demonstrated that the NC1 domain of FB-rhC7
interacts with ﬁbronectin (Chen et al., 1997b). To evaluate the
ability of puriﬁed CHO-rhC7 to bind to ﬁbronectin, we
subjected both CHO-rhC7 and FB-rhC7 to our solid-phase
ligand-binding assays. As shown in Figure 2a, CHO-rhC7 binds
to ﬁbronectin similar to FB-rhC7 in a dose-dependent manner.
We previously demonstrated that rhC7 isolated from
ﬁbroblasts promotes skin cell migration. Therefore, we
assessed the ability of rhC7 isolated from CHO cells to
promote the migration of human keratinocytes (Woodley
et al., 2008). Figure 2b shows representative microscopic
ﬁelds. CHO-rhC7 strongly promoted human keratinocyte
migration at levels similar to those generated by FB-rhC7. In
contrast, laminin 1 failed to promote keratinocyte migration.
These data indicate that, similar to FB-rhC7, CHO-rhC7 is a
potent promotility matrix for human keratinocytes.
Intravenously injected CHO-rhC7 distributed to multiple skin
sites, tongue and esophagus in RDEB mice
To evaluate the feasibility of intravenous protein replacement
therapy for RDEB, we tested the ability of intravenously
injected CHO-rhC7 to correct the RDEB phenotype in murine
C7-knockout mice (Col7a1− /−) that recapitulate the clinical,
genetic, immunohistochemical, and ultrastructural character-
istics of severe human RDEB. Neonatal Col7a1− /− mice were
administered a single intravenous injection of 16 μg of CHO-
rhC7 (n= 53) or a vehicle control (n=23) via the superﬁcial
temporal vein. Tissue sections from various skin and internal
sites were then obtained 1 week after initial injection and
subjected to immunostaining with a polyclonal rabbit anti-
body that recognized the amino-terminal noncollagenous
domain (NC1) of human C7. As shown in Figure 3a (top two
rows), the injected CHO-rhC7 distributed and incorporated
into the DEJ of multiple skin sites including abdomen, back,
front leg, rear leg, chest, head, front and back paw, and
tongue and esophagus. No C7 was found at any site when
C7-knockout mice were injected with vehicle (Figure 3a,
bottom row). Moreover, the injected CHO-rhC7 was detected
at the DEJ of tongue and esophagus up to 5 months after a
single injection (Supplementary Figure S1 online). Our data
provide evidence that the intravenously administered CHO-
rhC7 distributes to the tongue and esophagus that would not
be accessible by topical or intradermal therapies.
After demonstrating that intravenously administered CHO-
rhC7 distributed to the DEJ of the RDEB mouse’s skin wounds,
we next determined whether there is a dose-dependent
distribution to the DEJ. We intravenously injected neonatal
RDEB mice with 0 μg (n=12), 5 μg (n= 16), 16 μg (n= 25),
and 28 μg (n=11) of CHO-rhC7. We then killed the mice
4 days after injection and examined a single organ, the
tongue, for the distribution of CHO-rhC7. As shown in
Figure 3b, there was a dose-dependent increase in the
incorporation of CHO-rhC7 into the mouse’s DEJ.
Next, we wanted to know whether intravenously injected
CHO-rhC7 protein also distributed to non-target tissues. We
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Figure 2. Chinese hamster ovary–derived recombinant type VII collagen (CHO-rhC7) and recombinant human C7 puriﬁed from human dermal ﬁbroblasts (FB-
rhC7) bind to ﬁbronectin and promote keratinocyte migration. (a) ELISA plates were coated with ﬁbronectin (20 μgml−1) and then incubated with the indicated
concentrations of CHO-rhC7 or FB-rhC7 at 4 °C overnight. Binding was detected using rabbit anti-N-terminal noncollagenous domain of type VII collagen (NC1)
polyclonal antibodies (1:1000), followed by an alkaline phosphatase–conjugated secondary antibody (1:300). Error bars, SE of three different experiments. (b)
Left: Colloidal gold migration assay: Coverslips were coated with colloidal gold, and keratinocytes were plated on CHO-rhC7, FB-rhC7, laminin 1, or no matrix
(NO) at the indicated amounts and incubated for 18 h. Representative ﬁelds were photographed at × 40 under dark-ﬁeld optics. Error bars, SE of three different
experiments. Right: Migration index–– the percentage of total ﬁeld area consumed by the migration tracks. Error bars, SE of three different experiments. Note that
CHO-rhC7 promotes keratinocyte migration as effectively as FB-rhC7, in a dose-dependent manner.
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examined tissue sections from stomach, tongue, small intes-
tine, brain, kidney, liver, lung, spleen, and heart 2 to 3 weeks
following a single intravenous injection and subjected them to
immunostaining with an antibody speciﬁc for C7. The rhC7
was only readily observed in the tongue but not in any organs
described above (Supplementary Figure S2 online).
Intravenously administered CHO-rhC7 improved the
epidermal–dermal adherence and increased survival of the
RDEB mice
We next determined whether intravenously administered
CHO-rhC7 could reverse the RDEB phenotype of the RDEB
mice. Histological analysis of multiple skin sites from intra-
venously injected RDEB mice revealed markedly improved
dermal–epidermal adherence as shown in Figure 4a. In
contrast, the skin from the vehicle control-injected RDEB mice
continued to exhibit poor dermal–epidermal adherence.
As RDEB mice typically die within the ﬁrst week of life
(Heinonen et al., 1999), we also determined their survival
over time following a single intravenous administration of
CHO-rhC7. The Kaplan–Meier curve revealed that a single
intravenous administration of CHO-rhC7 signiﬁcantly
increased the survival of RDEB mice (Figure 4b) compared
with vehicle-treated mice (log-rank P-value o0.001). The
median overall survival was 12 days for CHO-rhC7-injected
mice compared with 3 days for vehicle-injected RDEB mice,
implying a 4-fold prolongation of survival time. Of note, 14 of
the 53 (26%) CHO-rhC7-injected mice survived beyond
8 weeks after receiving a single intravenous infusion with
16 μg of CHO-rhC7. Therefore, intravenous CHO-rhC7
administered to RDEB mice not only corrected their skin
RDEB phenotype but also improved their survival.
Formation of AFs following intravenous administration of CHO-
rhC7 in RDEB mice
We next sought to determine whether the CHO-rhC7 could
form AFs at the DEJ in vivo. Transmission immunoelectron
microscopy was performed on the tongue of RDEB mice after
the intravenous administration of CHO-rhC7. As shown in
Figure 5, intravenous administered CHO-rhC7 incorporated
into the mouse’s DEJ. As expected, there were no detectable
AFs in mice treated with vehicle control. Taken together,
these data indicate that protein-based therapy by intravenous
injection of CHO-rhC7 can correct the abnormal RDEB
dermal–epidermal separation and restore C7 expression and
AF formation at the DEJ in RDEB mice.
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Figure 3. Intravenously injected Chinese hamster ovary–derived recombinant type VII collagen (CHO-rhC7) distributed to the multiple sites of recessive
dystrophic epidermolysis bullosa (RDEB) mice. (a) Newborn RDEB mice were intravenously injected with 16 μg of CHO-rhC7 or vehicle control via the
superﬁcial temporal vein, and various tissue samples were obtained 5 to 14 days after mice were injected and subjected to immunoﬂuorescence (IF) staining with
an anti-N-terminal noncollagenous domain of type VII collagen (NC1) antibody. Note that intravenously injected CHO-rhC7 readily transported and incorporated
into the dermal–epidermal junction (DEJ) of multiple skin sites (top two rows) whereas none was detected in vehicle-injected mice (bottom row). (b) IF staining
with an anti-NC1 antibody was performed on mouse tongues 4 days following intravenous administration of various doses of CHO-rhC7, as indicated. Note a
dose-dependent increase in the deposition of CHO-rhC7 at the mouse DEJ. Error bars, SE of three different injected mice. Bar=200 μm. Abd, abdomen; Eso,
esophagus; FL, front leg; FP, front paw; RL, rear leg; RP, rear paw; Ton, tongue.
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A single intravenous administration of CHO-rhC7 in neonatal
RDEB mice does not induce anti-C7 antibodies
We next examined whether intravenously injected CHO-rhC7
would induce an immune response in neonatal RDEB mice.
Speciﬁcally, we looked for the induction of anti-C7 antibodies
in the blood and skin of these mice after a single intravenous
CHO-rhC7 administration. Sera from CHO-rhC7-injected
mice (n=12) were taken at 30 and 60 days following a
single intravenous administration of CHO-rhC7 and then
subjected to a commercially available ELISA for anti-C7
antibodies. Interestingly, there were no detectable anti-C7
antibodies in all 12 mice examined at both time points
(Supplementary Figure S3 online). In addition, direct immu-
noﬂuorescence staining performed on the skin of RDEB mice
treated with intravenous CHO-rhC7 was negative for IgG
deposits at the DEJ, despite the presence of human C7 at their
DEJ (Supplementary Figure S4 online).
DISCUSSION
Protein replacement therapy has been successful in a number
of hereditary diseases other than RDEB, including hereditary
angioedema, Gaucher’s disease, Fabry’s disease, and others
(Schiffmann et al., 2001; Beutler, 2004; Desnick, 2004;
Leader et al., 2008; Cicardi and Zanichelli, 2010). CHO cells
are widely used for large-scale production of therapeutic
recombinant proteins. In this paper, we demonstrated that
CHO cells generate high-quality rhC7 that behaves similar to
FB-rhC7, both structurally and functionally.
In the study herein, we demonstrated that intravenously
injected CHO-rhC7 distributed and incorporated into multiple
skin sites (legs, paws, back, abdomen, and chest), and the
tongue and esophagus of RDEB-like C7-knockout mice. We
noticed that strong C7 staining was often detected in the
tongue, front and back paws, and the front leg. It is possible
that these sites are more trauma-prone areas with consistent
wounds and immature vessels that allow more intravenous C7
to extravasate from the blood into the skin and incorporate
into the DEJ. In addition, we detected CHO-rhC7 in the
esophagus. These data provide direct evidence that an
intravenous administration in RDEB mice is capable of
delivering CHO-rhC7 to affected areas including the posterior
oral cavity and esophagus.
RDEB mice typically die within the ﬁrst week of life
(Heinonen et al., 1999). In this study, we found that
intravenously administered CHO-rhC7 signiﬁcantly increases
the survival of RDEB mice. This is most likely because the
intravenously injected C7 incorporates into multiple wide-
spread skin and mucosal wounds improving the dermal–
epidermal adherence, which allows the mice to live beyond
this critical ﬁrst week of life. Once past this critical period, we
speculate that hair growth in the animals may provide
additional protection and lessen new blister formation. It is
conceivable that the formation of mature hairs traversing both
the dermis and the epidermis of the skin may provide some
intrinsic epidermal–dermal adherence. In addition, the
incorporation of CHO-rhC7 into the DEJ of the animal’s
tongue and esophagus may also contribute to their increased
survival by allowing them to eat solid food once they weaned
off the mother’s milk. In our previous study using an
intradermal injection approach for administering the FB-
rhC7, the median survival of the RDEB mice receiving FB-
rhC7 was 5 weeks (Remington et al., 2009). In the present
study, the median survival of the RDEB mice receiving CHO-
rhC7 was 12 days. It is important to point out, however, that
the experiments are not at all comparable. In the intradermal
FB-rhC7 administration experiments, the FB-rhC7 was admi-
nistered multiple times (once every day for the ﬁrst week and
then weekly thereafter) with cumulative total FB-rhC7 doses
between 20 and 300 μg. In contrast, in our present study,
herein using an intravenous approach, the RDEB mice only
received one single dose of 16 μg of CHO-rhC7.
In our previous study, using RDEB mice that were injected
intradermally with FB-rhC7, we observed that the mice
developed circulating anti-C7 antibodies within 1 month after
injection and that the titers of these antibodies remained the
same for more than 6 months (Remington et al., 2009).
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Figure 4. Intravenous Chinese hamster ovary derived recombinant type VII
collagen (CHO-rhC7) improved epidermal–dermal adherence and increased
survival of recessive dystrophic epidermolysis bullosa (RDEB) mice. (a)
Multiple tissue samples, as indicated, from RDEB mice intravenously injected
with CHO-rhC7 or vehicle control were obtained 5 to 14 days after injection
and subjected to hematoxylin and eosin (H&E) staining. Note that the vehicle-
injected RDEB sections showed histological evidence of dermal–epidermal
separation. In contrast, CHO-rhC7-injected RDEB skin exhibited good
dermal–epidermal adherence. (b) Kaplan–Meier curves showing survival
comparison between vehicle control (n= 23) and CHO-rhC7 (n=53)-injected
RDEB mice. There is a signiﬁcant improvement in the survival of RDEB mice
administered CHO-rhC7 in comparison with vehicle control (log-rank
Po0.001). Bar=200 μm. Abd, abdomen; FL, front leg; FP, front paw; RL, rear
leg; RP, rear paw; Ton, tongue.
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Nevertheless, these mouse anti-C7 antibodies did not deposit
in the DEJ of the skin of the mice, despite an abundance of
human C7 at their DEJ. In the present study, which used
intravenous administration of CHO-rhC7, however, we did
not detect any anti-C7 antibodies in the blood or skin of the
mice. In these studies, a single intravenous injection was
performed within the neonatal period (within 24 or 48 hours
after birth), which is when the developing immune system is
particularly susceptible to the induction of tolerance. We
speculate that tolerance induction to C7 may be responsible
for the lack of the immune responses and the absence of anti-
C7 antibodies in these mice. Neonatal gene transfer and
neonatal protein injection have the potential to reduce
immune responses because newborn immune systems are
immature. For example, the induction of immune tolerance
by neonatal intravenous injection of human factor VIII into
hemophilia A–deﬁcient mice has been reported (Madoiwa
et al., 2004). Similarly, there were no antibodies detected in
hemophilia B dogs after injection of recombinant factor IX
protein or gene therapy with retroviral vectors expressing
factor IX (Xu et al., 2003).
In general, therapeutic proteins have limited half-lives
in vivo and require repeated administration to maintain
therapeutic efﬁcacy. For an example, frequent injections or
infusions of replacement proteins were needed for patients
suffering with hemophilia (Batorova et al., 2010).
Nevertheless, in our previous study, using rhC7 puriﬁed
from gene-corrected RDEB ﬁbroblasts, we showed that
intradermally injected FB-rhC7 stably incorporated into the
DEJ of RDEB mice and persisted there for at least 2 months
(Remington et al., 2009). Similarly, our study with human
RDEB skin equivalents transplanted onto immunodeﬁcient
mice also found that FB-rhC7 administered to skin equivalents
endures for at least 3 months (Woodley et al., 2004a). In the
present study, using CHO-rhC7, we were still able to detect
low levels of C7 in the tongue and esophagus even at
5 months after injection in a subset of mice. Therefore, it
appears that CHO-rhC7 has a comparable in vivo half-life as
FB-rhC7, although additional studies are needed to determine
the exact tissue half-life of CHO-rhC7. It should be pointed
out that there may be an advantage working with collagen as
a therapeutic agent, because collagens in general have slow
turnover times and are stable long-lived molecules (Pelkonen
and Kivirikko, 1970; Burgeson, 1993). In the case of RDEB, it
is known that one does not need 100% of the normal levels of
C7 or AFs to exhibit physiologically normal epidermal–
dermal adherence. In fact, it is estimated that only about 35%
of the normal AF complement is required to provide clinically
sufﬁcient dermal–epidermal adherence (Fritsch et al., 2008).
In the present study, quantifying the immunoﬂuorescence
intensity by the Image J analysis of RDEB mice intravenously
injected with 16 μg of CHO-C7 revealed that one injection
restored 25–50% of the normal C7 level at the DEJ in selected
areas of tongue and paws. As the maximum volume that can be
injected into newborn RDEB mice is 40 μl, this prevents us from
evaluating the upper limit of C7 that we can use to achieve
maximum C7 levels at the DEJ. In summary, we demonstrated
that puriﬁed CHO-rhC7 has similar structural and functional
properties of FB-rhC7. In addition, we showed that intravenous
injection of CHO-rhC7 into neonatal RDEB mice led to res-
toration of C7 and AFs at the DEJ of murine RDEB skin, tongue,
and esophagus with signiﬁcant beneﬁcial effects including
decreased skin fragility and blistering, improved epidermal–
dermal adherence, and improved survival. In addition, systemic
delivery of extracellular matrix molecules may represent a
potential therapeutic strategy for other skin disorders because of
defects in genes coding for other structural proteins in the skin.
MATERIALS AND METHODS
Cell culture
Primary human keratinocytes were purchased from Cascade
Biologics (Portland, OR) and cultured in low calcium, serum-free
keratinocyte growth medium supplemented with bovine pituitary
extract and epidermal growth factor (Gibco BRL, Gaithersburg, MD)
as described by Boyce and Ham (1983) and modiﬁed by O’Keefe and
Chiu (1988). Third or fourth passage keratinocytes were used for cell
migration studies.
Expression and puriﬁcation of CHO-rhC7
The CHO-rhC7 material for the studies was provided by Shire and
produced by cell culture and puriﬁcation methods known in the art.
Some methods are described elsewhere (De Souza and Viswanathan,
2013). FB-rhC7 was puriﬁed as described previously (Chen et al.,
2002b; Woodley et al., 2004a).
Protein-binding assay
The binding of soluble C7 to immobilized ﬁbronectin (purchased
from Life Technology, Gaithersburg, MD) was measured using a
colorimetric enzyme-linked antibody assay as described previously
(Chen et al., 1997b).
Proteases digestion
Puriﬁed recombinant C7 was incubated with chymotrypsin (Sigma, St
Louis, MO) at an enzyme-to-substrate ratio of 1:2 by weight in 50mM
Vehicle CHO-rhC7
DE
D
E
AF
HD
Figure 5. Intravenously injected CHO-rhC7 formed anchoring ﬁbrils (AFs) in
recessive dystrophic epidermolysis bullosa (RDEB) mice. Transmission
electron microscopy was performed on the tongues of RDEB mice
intravenously injected with either vehicle control (4 days) or Chinese hamster
ovary–derived recombinant type VII collagen (CHO-rhC7) at 14 days after
injection. Note that there were no identiﬁable AFs in vehicle-injected mice. In
contrast, intravenously-injected CHO-rhC7 incorporated into the RDEB skin’s
dermal–epidermal junction (DEJ) and formed AFs as indicated by arrows.
Bar=500 nm for the low magniﬁcation image and 200 nm for the high
magniﬁcation insert. D, dermis; E, epidermis; HD, hemidesmosome.
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Tris-HCl, pH 7.4, 150mM NaCl at 37 °C for 3 hours and then
analyzed by SDS-PAGE, followed by immunoblot analysis with a
polyclonal antibody against the collagenous domain of C7, as
described previously (Chen et al., 2002a; Woodley et al., 2008).
Cell migration assay
Keratinocyte migration was assayed by the method of Albrecht-
Buehler (1977), as modiﬁed by Woodley et al. (1988).
Animal studies
Col7a1+/− animals were developed as described previously
(Heinonen et al., 1999) and maintained at the animal facilities of
the University of Southern California, Los Angeles, California under
guidelines for the care and use of animals in research. All animal
studies were conducted using protocols approved by the University
of Southern California Institutional Animal Use Committee. For
protein therapy, we intravenously injected newborn RDEB mice with
either 16 μg of CHO-rhC7 suspended in 40 μl of vehicle buffer
(n= 53) or 40 μl of vehicle alone (n= 23) via the superﬁcial temporal
vein. At various times after intravenous administration of rhC7 or
vehicle control, the RDEB mice were biopsied at multiple skin
mucosal sites including abdomen, back, front leg, rear leg, chest, and
tongue and esophagus, and the skin specimens were subjected to
immunostaining using a rabbit polyclonal antibody recognizing the
NC1 domain of human C7 (Chen et al., 1997a) as described below.
Histological sections of the mouse skin specimens were ﬁxed in 10%
buffered formalin and stained with hematoxylin and eosin (H&E).
Blood samples were taken at the indicated times from the tail vein
and then stored at 4 °C overnight.
Immunoﬂuorescence staining and ultrastructural analysis of
tissue
Immunolabeling of the tissue was performed using standard
immunoﬂuorescence methods as described previously (Woodley
et al., 2004a; Remington et al., 2009). Transmission electron
microscopy was performed on the mouse tongue using a
standardized method as described previously (Keene et al., 1987;
Sakai and Keene, 1994).
ELISA using recombinant NC1 and NC2
The production of circulating anti-C7 antibodies was evaluated by
ELISA with NC1 and NC2 domains of C7 following the manufac-
turer’s procedure using mouse’s serum at a dilution of 1:100 (MBL,
Nagoya, Japan).
To evaluate whether there are any anti-C7 antibodies deposited
directly in the skin, RDEB mouse skin specimens from CHO-rhC7-
positive areas were subjected to direct immunoﬂuorescence staining
using FITC–conjugated goat anti-mouse IgG (Sigma), as described
previously (Woodley et al., 1984).
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